Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Alexandra G. Jacob"'
Publikováno v:
Blood. 138:4377-4377
Background: Response in acute myeloid leukemia (AML) is based on morphologic evaluation of bone marrow (BM) and peripheral blood lab-based assessments. Electronic health records (EHRs) hold structured information on peripheral blood assessments, but
Autor:
Kathleen Maignan, Scott F. Huntington, Ian J. Hooley, Angelica Medina, Lauren Benderoff, Alexandra G. Jacob, Robert T. Chen
Publikováno v:
Blood. 136:43-44
Introduction: Hypogammaglobulinemia is a known potential adverse event in patients with CLL receiving anti-CD20 monoclonal antibody (mAb) therapy. However, real-world immunoglobulin G (IgG) testing rates have not been extensively studied. We used a r
Autor:
Susan E. Prockop, Sergio Giralt, Ioannis Politikos, Andromachi Scaradavou, Genovefa A. Papanicolaou, Gunjan L. Shah, Richard J. O'Reilly, Juliet N. Barker, Alexandra G. Jacob, Parastoo B. Dahi, Carmen Lau, Valkal Bhatt, Miguel-Angel Perales, Sean M. Devlin, Kristine Naputo, Aishat Afuye, Doris M. Ponce, Molly Maloy
Publikováno v:
Biology of Blood and Marrow Transplantation. 24:S379-S380
Autor:
Hugo Castro-Malaspina, Jonathan U. Peled, Ann A. Jakubowski, Craig S. Sauter, Andromachi Scaradavou, Miguel-Angel Perales, James W. Young, Ioannis Politikos, Marcel R.M. van den Brink, Parastoo B. Dahi, Molly Maloy, Sergio Giralt, Kristine Naputo, Aishat Afuye, Roni Tamari, Juliet N. Barker, Brian C. Shaffer, Sean M. Devlin, Alan M. Hanash, Boglarka Gyurkocza, Esperanza B. Papadopoulos, Valkal Bhatt, Gunjan L. Shah, Alexandra G. Jacob, Richard J. O'Reilly, Doris M. Ponce
Publikováno v:
Biology of Blood and Marrow Transplantation. 24:S188-S189
Autor:
Andromachi Scaradavou, Ann A. Jakubowski, James W. Young, Scott T. Avecilla, Richard J. O'Reilly, Ioannis Politikos, Brian C. Shaffer, Molly Maloy, Esperanza B. Papadopoulos, Boglarka Gyurkocza, Christopher Mazis, Craig S. Sauter, Sergio Giralt, Gunjan L. Shah, Alexandra G. Jacob, Sean M. Devlin, Roni Tamari, Marcel R.M. van den Brink, Doris M. Ponce, Hugo Castro-Malaspina, Jonathan U. Peled, Juliet N. Barker, Parastoo B. Dahi, Kristine Naputo, Aishat Afuye, Miguel-Angel Perales
Publikováno v:
Biology of Blood and Marrow Transplantation. 24:S187-S188
Autor:
Stephanie L. Verwys, Anas Younes, Audrey Hamilton, Gianna N. McArthur, Zhigang Zhang, Steven M. Horwitz, Paul M. Barr, Joachim Yahalom, Craig H. Moskowitz, Susan J. McCall, Matthew J. Matasar, Philip Caron, Andrew D. Zelenetz, Maria Lia Palomba, John F. Gerecitano, Ariela Noy, Jonathan W. Friedberg, Joanna C. Yang, Alexandra G. Jacob, Carla Casulo, Louis S. Constine, April Chiu, Paul A. Hamlin, Anita Kumar, Carol S. Portlock, David J. Straus, Nicholas VanderEls, Alison J. Moskowitz, Pamela Drullinsky, Heiko Schöder
Publikováno v:
Blood. 128(11)
This multicenter pilot study assessed the safety and efficacy of brentuximab vedotin (BV) and AVD (adriamycin, vinblastine, and dacarbazine) followed by 30 Gy involved site radiation therapy (ISRT). Patients with newly diagnosed, early stage classica
Autor:
Jennifer W. Anderson, Pier Luigi Zinzani, Karen M. Giallella, Philippe Armand, Margaret A. Shipp, Martin Gutierrez, Shelonitda Rose, Martha Derosier, Craig H. Moskowitz, Alexandra G. Jacob, Vincent Ribrag, Eric J. Rubin, Guadalupe De Maeyer, Giovanni Martinelli, Jean-Marie Michot, Joy Wang, Zijiang Yang
Publikováno v:
Blood. 124:290-290
The programmed death-1 (PD-1) pathway serves as an immune checkpoint to temporarily dampen immune responses upon chronic antigen stimulation. Normal antigen presenting cells and certain tumor cells express the PD-1 ligands, PD-L1 and PD-L2, which eng
Autor:
Carol S. Portlock, Stephanie L. Verwys, Andrew D. Zelenetz, Zhigang Zhang, John F. Gerecitano, Craig H. Moskowitz, Heiko Schöder, Alison J. Moskowitz, Lia Palomba, Alexandra G. Jacob, Audrey Hamilton, Anita Kumar, Susan J. McCall, Paul A. Hamlin, Ariela Noy, Philip Caron, Anas Younes, David J. Straus, Joachim Yahalom, Matthew J. Matasar, Pamela Drullinsky, Steven M. Horwitz
Publikováno v:
Memorial Sloan Kettering Cancer Center
Background: Brentuximab vedotin has not been previously studied in combination with combined modality therapy for the frontline treatment of early stage Hodgkin lymphoma. We designed a pilot study to assess the safety and early efficacy of four cycle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43c3dc7ce17bc32aa46373bf34c2e8bb
https://synapse.mskcc.org/synapse/works/71447
https://synapse.mskcc.org/synapse/works/71447